News | March 25, 2015

Complete Angioplasty Safe for Certain Heart Attack Survivors

Proactive follow-up procedure may reduce future angioplasty or bypass

March 25, 2015 — Patients who experience the deadliest form of heart attack — ST-segment elevation myocardial infarction (STEMI) — and suffer from substantial narrowing in multiple heart arteries may benefit from receiving angioplasty in constricted arteries not affected by the heart attack, thereby reducing the need for future angioplasty, according to research presented at the 2015 American College of Cardiology (ACC) Annual Scientific Session. 
The study, the Third DANish Study of Optimal Acute Treatment of Patients with ST-segment Elevation Myocardial Infarction: PRImary PCI in MULTIvessel Disease, is the largest prospective, controlled trial to evaluate whether patients should receive preventive angioplasty (called complete angioplasty) after receiving emergency angioplasty in response to a heart attack. A total of 627 STEMI patients in Denmark who survived an initial angioplasty procedure were randomized to receive either standard follow-up care or complete revascularization two days after the emergency procedure. 
After an average of 27 months, 17 percent of the patients who received standard care returned for unplanned angioplasty or bypass surgery compared to only 5 percent of the patients who received complete revascularization. Rates of heart attack and death were comparable between the two groups. 
Of the patients who returned for unplanned angioplasty, more than 40 percent of patients in both groups were considered urgent revascularizations. 
“Our results show that it is safe to do a complete revascularization in this particular patient population,” said Thomas Engstrøm, M.D., Ph.D., senior consultant at the University of Copenhagen and the study’s lead author. “We think this approach should be implemented in the guidelines, as it may help patients avoid returning for future angioplasty in an urgent manner.” 
While this approach was found to reduce the likelihood of unplanned angioplasty or bypass, the study authors were surprised to find there were no significant differences in rates of death or repeat heart attacks.
“The neutral impact from complete revascularization on death and repeat heart attacks is informative for physicians [because] if their patients have other risk factors, like poor compliance with dual antiplatelet medical therapy or a need for complex angioplasty that may lead to unsuccessful results, a more conservative approach can be taken without increasing the risk for death or heart attacks,” he said.
Each year nearly 250,000 Americans experience STEMI, a severe form of heart attack that requires immediate angioplasty and is caused by prolonged blockage of blood supply in the heart. About 40 percent of STEMI patients are found to have narrowing of other coronary arteries in addition to the one with the blockage that caused their heart attack — a condition called multivessel disease. Multivessel disease can substantially increase the risk of death and other cardiac events, such as repeat heart attacks or need for urgent angioplasty. According to the study authors, there is no consensus regarding treatment of multivessel disease; therefore, approaches to reduce the risk are needed.
Angioplasty is a non-surgical procedure in which a balloon is fed into the blood vessels through a catheter and inflated to open narrowed or blocked arteries, allowing blood to flow. A stent is often placed at the site of blockage to open the artery. If the blockage is too severe, a patient will undergo heart bypass surgery to replace damaged arteries with blood vessels from another area of the body.
The trial, which took place in Denmark, included patients who underwent successful angioplasty for STEMI and had multivessel disease with narrowing of at least 50 percent, as well as a fractional flow reserve (FFR) of less than 0.80 measured with a guide wire-based procedure that can accurately measure blood pressure and flow through a specific part of the coronary artery.
The results add to mounting evidence showing preventive revascularization to be beneficial in certain patients. Current U.S. guidelines recommend a more gradual approach in which angioplasty is performed once patients begin to experience symptoms related to multivessel disease.
Engstrøm said research is needed to look into whether or not complete angioplasty can be conducted earlier than two days post-STEMI. The researchers’ rationale for this timeframe — two days after the initial procedure — was to let the patient’s body recover and to allow for more accurate identification of arteries in need of angioplasty.
The study was funded by the Danish Agency for Science, Technology and Innovation and the Danish Council for Strategic Research.
For more information:

Related Content

New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
Overlay Init